Structural Dynamics and Catalytic Mechanism of ATP13A2 (PARK9) from Simulations
Author:
Mateeva TeodoraORCID, Klähn Marco, Rosta Edina
Abstract
AbstractATP13A2 is a gene encoding a protein of the P5B subfamily of ATPases and is a PARK gene. Molecular defects of the gene are mainly associated with variations of Parkinson’s Disease (PD). Despite the established importance of the protein in regulating neuronal integrity, the three-dimensional structure of the protein currently remains unresolved crystallographically. We have modelled the structure and reactivity of the full-length protein in its E1-ATP state. Using Molecular Dynamics (MD), Quantum cluster and Quantum Mechanical/Molecular mechanical (QM/MM) methods, we aimed at describing the main catalytic reaction, leading to the phosphorylation of Asp513. Our MD simulations suggest that two positively charged Mg2+ cations are present at the active site during the catalytic reaction, stabilizing a specific triphosphate binding mode. Using QM/MM calculations, we subsequently calculated the reaction profiles for the phosphoryl transfer step in the presence of one and two Mg2+ cations. The calculated barrier heights in both cases are found to be ∼12.5 and 7.0 kcal mol-1, respectively. We elucidated details of the catalytically competent ATP conformation and the binding mode of the second Mg2+ cofactor. We also examined the role of the conserved Arg686 and Lys859 catalytic residues. We observed that by lowering significantly the barrier height of the ATP cleavage reaction, Arg686 had significant effect on the reaction. The removal of Arg686 increased the barrier height for the ATP cleavage by more than 5.0 kcal mol-1 while the removal of key electrostatic interactions created by Lys859 to the γ-phosphate and Asp513 destabilizes the reactant state. When missense mutations occur in close proximity to an active site residue, they can interfere with the barrier height of the reaction, which can halt the normal enzymatic rate of the protein. We also found large binding pockets in the full-length structure, including a transmembrane domain pocket, which is likely where ATP13A2 cargo binds.
Publisher
Cold Spring Harbor Laboratory
Reference66 articles.
1. Park, J. S. , Blair, N. F. , Sue, C. M. The Role of ATP13A2 in Parkinson’s Disease: Clinical Phenotypes and Molecular Mechanisms. Mov. Disord. 2015. https://doi.org/10.1002/mds.26243. 2. van Veen, S. , Sørensen, D. M. , Holemans, T. , Holen, H. W. , Palmgren, M. G. , Vangheluwe, P. Cellular Function and Pathological Role of ATP13A2 and Related P-Type Transport ATPases in Parkinson’s Disease and Other Neurological Disorders. Frontiers in Molecular Neuroscience. 2014. https://doi.org/10.3389/fnmol.2014.00048. 3. Unlocking Atp13a2/Park9 Activity;Cell Cycle,2015 4. Holemans, T. , Sørensen, D. M. , Van Veen, S. , Martin, S. , Hermans, D. , Kemmer, G. C. , Van Den Haute, C. , Baekelandt, V. , Pomorski, T. G. , Agostinis, P. , Wuytack, F. , Palmgren, M. , Eggermont, J. , Vangheluwe, P. A Lipid Switch Unlocks Parkinson’s Disease-Associated ATP13A2. Proc. Natl. Acad. Sci. U. S. A. 2015. https://doi.org/10.1073/pnas.1508220112. 5. Podhajska, A. , Musso, A. , Trancikova, A. , Stafa, K. , Moser, R. , Sonnay, S. , Glauser, L. , Moore, D. J. Common Pathogenic Effects of Missense Mutations in the P-Type ATPase ATP13A2 (PARK9) Associated with Early-Onset Parkinsonism. PLoS One 2012. https://doi.org/10.1371/journal.pone.0039942.
|
|